Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer
Autor: | Joanna Budna-Tukan, Catherine Alix-Panabières, Michał Nowicki, Wojciech A Cieślikowski, Agnieszka Ida, Andrzej Antczak, Monika Świerczewska, Agnieszka Jankowiak, Maciej Zabel, Michał Hrab, Martine Mazel, Klaus Pantel, Piotr Milecki |
---|---|
Přispěvatelé: | Poznan University of Medical Sciences [Poland] (PUMS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), University of Wrocław [Poland] (UWr), University of Zielona Góra |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty circulating tumor cells (CTCs) medicine.medical_treatment [SDV.CAN]Life Sciences [q-bio]/Cancer Disease [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology lcsh:RC254-282 Article 03 medical and health sciences Prostate cancer 0302 clinical medicine Circulating tumor cell Internal medicine medicine Disseminated disease Stage (cooking) metastases early detection radiotherapy business.industry Cancer lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens prostate cancer medicine.disease 3. Good health Radiation therapy 030104 developmental biology 030220 oncology & carcinogenesis Localized disease business |
Zdroj: | Cancers Volume 12 Issue 1 Cancers, Vol 12, Iss 1, p 160 (2020) Cancers, MDPI, 2020, 12 (1), pp.160. ⟨10.3390/cancers12010160⟩ |
ISSN: | 2072-6694 |
Popis: | The aim of this study was to investigate whether the enumeration of circulating tumor cells (CTCs) in blood can differentiate between true localized and metastatic prostate cancer. A cross-sectional study of 104 prostate cancer patients with newly diagnosed high-risk prostate cancer was conducted. In total, 19 patients presented metastatic disease and 85 were diagnosed with localized disease. Analyses included intergroup comparison of CTC counts, determined using the CellSearch® system, EPISPOT assay and GILUPI CellCollector® and ROC analysis verifying the accuracy of CTC count as a maker of disseminated prostate cancer. The vast majority (94.7%) of patients with advanced-stage cancer tested positively for CTCs in at least one of the assays. However, significantly higher CTC counts were determined with the CellSearch® system compared to EPISPOT assay and GILUPI CellCollector® Identification of &ge 4 CTCs with the CellSearch® system was the most accurate predictor of metastatic disease (sensitivity 0.500 specificity 0.900 AUC (95% CI) 0.760 (0.613&ndash 0.908). Furthermore, we tried to create a model to enhance the specificity and sensitivity of metastatic prediction with CTC counts by incorporating patient&rsquo s clinical data, including PSA serum levels, Gleason score and clinical stage. The composite biomarker panel achieved the following performance: sensitivity, 0.611 specificity, 0.971 AUC (95% CI), 0.901 (0.810&ndash 0.993). Thus, although the sensitivity of CTC detection needs to be further increased, our findings suggest that high CTC counts might contribute to the identification of high-risk prostate cancer patients with occult metastases at the time of diagnosis. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |